Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dongxia Gao

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Breast Cancer Research and Treatment|June 22, 2020
Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohortAngela S Cheng, Samuel C Y Leung, Dongxia Gao, et al.
Breast Cancer Research and Treatment|May 17, 2011
Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypesRinat Yerushalmi, Karen A Gelmon, Samuel Leung, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 1, 2020
Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor typesMayanne M T Zhu, Samantha Burugu, Dongxia Gao, et al.
BMC Cancer|March 15, 2014
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensTorsten Nielsen, Brett Wallden, Carl Schaper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical TrialsKarama Asleh, Dongsheng Tu, Dongxia Gao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 3, 2019
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomasAmanda R Dancsok, Nokitaka Setsu, Dongxia Gao, et al.
Plos One|July 31, 2009
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsKaty Milne, Martin Köbel, Steven E Kalloger, et al.
The Journal of Pathology|July 15, 2010
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomasMartin Köbel, Alexander Reuss, Andreas du Bois, et al.
Cancers|April 3, 2021
Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune CheckpointsShawn C Chafe, Nazia Riaz, Samantha Burugu, et al.
Cancers|August 12, 2022
Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical TrialElahe Shenasa, Elisabeth Specht Stovgaard, Maj-Britt Jensen, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Breast Cancer Research and Treatment|June 22, 2020
Correction to: Mismatch repair protein loss in breast cancer: clinicopathological associations in a large British Columbia cohortAngela S Cheng, Samuel C Y Leung, Dongxia Gao, et al.
Breast Cancer Research and Treatment|May 17, 2011
Insulin-like growth factor receptor (IGF-1R) in breast cancer subtypesRinat Yerushalmi, Karen A Gelmon, Samuel Leung, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 1, 2020
Evaluation of glucocorticoid-induced TNF receptor (GITR) expression in breast cancer and across multiple tumor typesMayanne M T Zhu, Samantha Burugu, Dongxia Gao, et al.
BMC Cancer|March 15, 2014
Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimensTorsten Nielsen, Brett Wallden, Carl Schaper, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 7, 2021
Predictive Significance of an Optimized Panel for Basal-like Breast Cancer: Results from the Canadian Cancer Trials Group MA.5 and MA.12 Phase III Clinical TrialsKarama Asleh, Dongsheng Tu, Dongxia Gao, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 3, 2019
Expression of lymphocyte immunoregulatory biomarkers in bone and soft-tissue sarcomasAmanda R Dancsok, Nokitaka Setsu, Dongxia Gao, et al.
Plos One|July 31, 2009
Systematic analysis of immune infiltrates in high-grade serous ovarian cancer reveals CD20, FoxP3 and TIA-1 as positive prognostic factorsKaty Milne, Martin Köbel, Steven E Kalloger, et al.
The Journal of Pathology|July 15, 2010
The biological and clinical value of p53 expression in pelvic high-grade serous carcinomasMartin Köbel, Alexander Reuss, Andreas du Bois, et al.
Cancers|April 3, 2021
Granulocyte Colony Stimulating Factor Expression in Breast Cancer and Its Association with Carbonic Anhydrase IX and Immune CheckpointsShawn C Chafe, Nazia Riaz, Samantha Burugu, et al.
Cancers|August 12, 2022
Neither Tumor-Infiltrating Lymphocytes nor Cytotoxic T Cells Predict Enhanced Benefit from Chemotherapy in the DBCG77B Phase III Clinical TrialElahe Shenasa, Elisabeth Specht Stovgaard, Maj-Britt Jensen, et al.
Pageof 6